VivoSeq
Oncology

Classic Hodgkin Lymphoma

41

Pipeline Programs↗

10

Active Trials↗

23

Companies Involved↗

Classic Hodgkin Lymphoma is a moderately active landscape with 41 programs across 23 companies. The most active players are Pfizer, Eli Lilly, Gilead. 15 therapies are approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

58/100

Pipeline Velocity

6/100

Mech. Concentration

10/100

Completion Rate

67/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

2 programs

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2Gilead logo

Gilead

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2G

Gynecologic Oncology Group

1 program

Phase 2Roche logo

Roche

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

28 of 42 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody1126%Protein / enzyme25%Antibody–drug conjugate12%

Small molecule leads; the ring shows all 42 classified programs, each share of the total. Modality classified for 100% of 42 pipeline programs.

Analysis

Trial Status

13

clinical trials

Recruiting5 · 38%
Active, not recruiting3 · 23%
Not yet recruiting2 · 15%
Completed2 · 15%
Terminated1 · 8%

Clinical Trials

Trial Activity

13 trials

Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma
Recruiting·SSun Yat-sen University·Phase 2·NCT05949931·108 enrolled
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
Recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 3·NCT06170489·185 enrolled
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
Recruiting·EEmory University·Phase 2·NCT05039073·46 enrolled
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
Recruiting·National Medical Research Radiological Centre of the Ministry of Health of Russia·Phase 2·NCT06984146·54 enrolled
A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
Recruiting·AAkeso·Phase 1/2·NCT06642792·280 enrolled
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05922904·25 enrolled
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
Active, not recruiting·—·Phase 2·NCT03712202·155 enrolled
A Phase II Multi-Center Open-Label Trial of Six Doses of Pembrolizumab Monotherapy Prior to Limited Chemotherapy as Front-Line Therapy for Patients With Classical Hodgkin Lymphoma, Including Elderly Patients.
Active, not recruiting·NNorthwestern University·Phase 2·NCT06164275·30 enrolled
Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma
Not yet recruiting·UUniversity of Cologne·Phase 2·NCT06916416·50 enrolled
Neurocognitive Assessment in Long-Term Survivors of Lymphoma: An Observational Study by the Fondazione Italiana Linfomi (FIL)
Not yet recruiting·FFondazione Italiana Linfomi - ETS·N/A·NCT07652476·100 enrolled
Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00654732·58 enrolled
A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma
Completed·AAkeso·Phase 1/2·NCT03722147·94 enrolled
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
Terminated·Pfizer logoPfizer·Phase 2·NCT03947255·12 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)